Is Insmed, Inc. overvalued or undervalued?

As of 22 February 2019, the valuation grade for Insmed, Inc. has moved from does not qualify to risky. The company is currently overvalued given its financial metrics and performance indicators. Notably, Insmed has a Price to Book Value of 135.23, an EV to EBIT of -15.70, and an ROCE of -483.80%, which highlight its significant financial struggles.
When comparing Insmed to its peers, Perrigo Co. Plc has a P/E ratio of -130.48, while Organon & Co. is rated very attractive with a P/E of 2.90. This stark contrast in valuation ratios suggests that Insmed is not only underperforming relative to its peers but also indicates a lack of investor confidence in its future profitability. Despite recent stock performance showing a 56.11% return over the past month, which outpaces the S&P 500's 3.83%, the underlying financial metrics suggest that Insmed remains overvalued in the current market environment.